João X Araújo-Júnior

Prof. João X Araújo-Júnior

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2018 in Marine Drugs
Verified
Journal Article
Open access
PDF file
ALAlessandra Marinho Miranda Lucena
Alessandra Marinho Miranda Lucena
CSCássio Souza
Cássio Souza
JJJéssica Jales
Jéssica Jales
PGPaulo Marcos da Matta Guedes
Paulo Marcos da Matta Guedes
GMGeorge E. C. De Miranda
George E. C. De Miranda
JSJaneusa Souto
Janeusa Souto
Caulerpin (CLP), an alkaloid from algae of the genus Caulerpa, has shown anti-inflammatory activity. Therefore, this study aimed to analyze the effect of CLP in the murine model of peritonitis and ulcerative colitis. Firstly, the mice were submitted to peritonitis to evaluate which dose of CLP (40, 4, or 0.4 mg/kg) could decrease the inflammatory infiltration in the peritoneum. The most effective doses were 40 and 4 mg/kg. Then, C57BL/6 mice were submitted to colitis development with 3% dextran sulfate sodium (DSS) and treated with CLP at doses of 40 and 4 mg/kg. The disease development was analyzed through the disease activity index (DAI); furthermore, colonic tissue samples were submitted to histological analysis, NFκB determination, and in vitro culture for cytokines assay. Therefore, CLP at 4 mg/kg presented the best results, triggering improvement of DAI and attenuating the colon shortening and damage. This dose was able to reduce the TNF-α, IFN-γ, IL-6, IL-17, and NFκB p65 levels, and increased the levels of IL-10 in the colon tissue. Thus, CLP mice treatment at a dose of 4 mg/kg showed promising results in ameliorating the damage observed in the ulcerative colitis.

1 November 2022 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Igor José dos Santos NascimentoIgor José dos Santos Nascimento
Igor José dos Santos Nascimento
ÉRÉrica Erlanny da Silva Rodrigues
Érica Erlanny da Silva Rodrigues
MSManuele Figueiredo da Silva
Manuele Figueiredo da Silva
JAJoão X Araújo-Júnior
João X Araújo-Júnior
RMRicardo Olímpio de Moura
Ricardo Olímpio de Moura
The Flaviviridae virus family consists of the genera Hepacivirus, Pestivirus, and Fla-vivirus, with approximately 70 viral types that use arthropods as vectors. Among these diseases, dengue (DENV) and zika virus (ZIKV) serotypes stand out, responsible for thousands of deaths worldwide. Due to the significant increase in cases, the World Health Organization (WHO) declared DENV a potential threat for 2019 due to being transmitted by infected travelers. Furthermore, ZIKV also has a high rate of transmissibility, highlighted in the outbreak in 2015, generating consequenc-es such as Guillain-Barré syndrome and microcephaly. According to clinical outcomes, those in-fected with DENV can be asymptomatic, and in other cases, it can be lethal. On the other hand, ZIKV has severe neurological symptoms in newborn babies and adults. More serious symptoms in-clude microcephaly, brain calcifications, intrauterine growth restriction, and fetal death. Despite these worrying data, no drug or vaccine is approved to treat these diseases. In the drug discovery process, one of the targets explored against these diseases is the NS2B-NS3 complex, which pre-sents the catalytic triad His51, Asp75, and Ser135, with the function of cleaving polyproteins, with specificity for basic amino acid residues, Lys- Arg, Arg-Arg, Arg-Lys or Gln-Arg. Since NS3 is highly conserved in all DENV serotypes and plays a vital role in viral replication, this complex is an excellent drug target. In recent years, computer-aided drug discovery (CADD) is increasingly essen-tial in drug discovery campaigns, making the process faster and more cost-effective, mainly ex-plained by discovering new drugs against DENV and ZIKV. Finally, the main advances in compu-tational methods applied to discover new compounds against these diseases will be presented here. In fact, molecular dynamics simulations and virtual screening is the most explored approach, providing several hit and lead compounds that can be used in further optimizations. In addition, fragment-based drug design and quantum chemistry/molecular mechanics (QM/MM) provides new insights for developing anti-DENV/ZIKV drugs. We hope that this review offers further helpful in-formation for researchers worldwide and stimulates the use of computational methods to find a promising drug for treating DENV and ZIKV.

1 August 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
Edeíldo Ferreira da Silva-JúniorEdeíldo Ferreira da Silva-Júnior
Edeíldo Ferreira da Silva-Júnior
GLGiovanni O. Leoncini
Giovanni O. Leoncini
ÉRÉrica E.S. Rodrigues
Érica E.S. Rodrigues
TAThiago Aquino
Thiago Aquino
JAJoão X Araújo-Júnior
João X Araújo-Júnior

1 February 2022 in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
TAThiago Aquino
Thiago Aquino
PFPaulo H. B. França
Paulo H. B. França
ÉRÉrica E. E. S. Rodrigues
Érica E. E. S. Rodrigues
Igor José dos Santos NascimentoIgor José dos Santos Nascimento
Igor José dos Santos Nascimento
PSPaulo F. S. Santos-Júnior
Paulo F. S. Santos-Júnior
JAJoão X Araújo-Júnior
João X Araújo-Júnior
Background: Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most severe, fatal in 95% of cases. The undesired side-effects from first-line chemotherapy and the reported drug resistance search for effective drugs that can replace or supplement those currently used in an urgent need. Aminoguanidine hydrazones (AGH's) have been explored for exhibiting a diverse spectrum of biological activities, in particular the antileishmanial activity of MGBG. The bioisosteres thiosemicarbazones (TSC's) offer a similar biological activity diversity, including antiprotozoal effects against Leishmania species and Trypanosoma cruzi. Objectives: Considering the impact of leishmaniasis worldwide, this work aimed to design, synthesize, and perform a screening upon L. chagasi amastigotes and for the cytotoxicity of the small "inhouse" library of both AGH and TSC derivatives and their structurally-related compounds. Methods: A set of AGH's (3-7), TSC's (9, 10), and semicarbazones (11) were initially synthesized. Subsequently, different semi-constrained analogs were designed and also prepared, including thiazolidines (12), dihydrothiazines (13), imidazolines (15), pyrimidines (16, 18) azines (19, 20), and benzotriazepinones (23-25). All intermediates and target compounds were obtained with satisfactory yields and exhibited spectral data consistent with their structures. All final compounds were evaluated against L. chagasi amastigotes and J774.A1 cell line. Molecular docking was performed towards trypanothione reductase using GOLD® software. Results: The AGH's 3i, 4a, and 5d, and the TSC's 9i, 9k, and 9o were selected as valuable hits. These compounds presented antileishmanial activity compared with pentamidine, showing IC50 values ranged from 0.6 to 7.27 μM, maximal effects up to 55.3%, and satisfactory SI values (ranged from 11 to 87). On the other hand, most of the resulting semi-constrained analogs were found cytotoxic or presented reduced antileishmanial activity. In general, TSC class is more promising than its isosteric AGH analogs, and the beneficial aromatic substituent effects are not similar in both series. In silico studies have suggested that these hits are capable of inhibiting the trypanothione reductase from the amastigote forms. Conclusion: The promising antileishmanial activity of three AGH’s and three TSC’s was characterized. These compounds presented antileishmanial activity compared with PTD, showing IC50 values ranged from 0.6 to 7.27 μM, and satisfactory SI values. Further pharmacological assays involving other Leishmania strains are in progress, which will help choose the best hits for in vivo experiments.

5 June 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
PFPaulo H. B. França
Paulo H. B. França
DBDaniel P. Barbosa
Daniel P. Barbosa
DSDaniel L. da Silva
Daniel L. da Silva
ÊRÊurica A. N. Ribeiro
Êurica A. N. Ribeiro
ASAntônio E. G. Santana
Antônio E. G. Santana
JAJoão X Araújo-Júnior
João X Araújo-Júnior
Indole alkaloids comprise a large and complex class of natural products found in a variety of marine sources. Infectious diseases remain a major threat to public health, and in the absence of long-term protective vaccines, the control of these infectious diseases is based on a small number of chemotherapeutic agents. Furthermore, the emerging resistance against these drugs makes it urgently necessary to discover and develop new, safe and, effective anti-infective agents. In this regard, the aim of this review is to highlight indole alkaloids from marine sources which have been shown to demonstrate activity against infectious diseases.

30 June 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GPGabriel Passos
Gabriel Passos
MGMatheus Gabriel Moura Gomes
Matheus Gabriel Moura Gomes
TAThiago Aquino
Thiago Aquino
JAJoão X Araújo-Júnior
João X Araújo-Júnior
SSStephannie Janaína Maia de Souza
Stephannie Janaína Maia de Souza
Edeíldo Ferreira da Silva-JúniorEdeíldo Ferreira da Silva-Júnior
Edeíldo Ferreira da Silva-Júnior
Chikungunya virus (CHIKV) causes an infectious disease characterized by inflammation and pain of the musculoskeletal tissues accompanied by swelling in the joints and cartilage damage. Currently, there are no licensed vaccines or chemotherapeutic agents to prevent or treat CHIKV infections. In this context, our research aimed to explore the potential in vitro anti-CHIKV activity of acrylamide derivatives. In silico methods were applied to 132 Michael’s acceptors toward the six most important biological targets from CHIKV. Subsequently, the ten most promising acrylamides were selected and synthesized. From the cytotoxicity MTT assay, we verified that LQM330, 334, and 336 demonstrate high cell viability at 40 µM. Moreover, these derivatives exhibited anti-CHIKV activities, highlighting the compound LQM334 which exhibited an inhibition value of 81%. Thus, docking simulations were performed to suggest a potential CHIKV-target for LQM334. It was observed that the LQM334 has a high affinity towards the E3-E2-E1 glycoproteins complex. Moreover, LQM334 reduced the percentage of CHIKV-positive cells from 74.07 to 0.88%, 48h post-treatment on intracellular flow cytometry staining. In conclusion, all virtual simulations corroborated with experimental results, and LQM334 could be used as a promising anti-CHIKV scaffold for designing new drugs in the future.